17 / 51
Immunology 2018
J u l y 0 5 - 0 7 , 2 0 1 8
V i e n n a , A u s t r i a
Page 80
Journal of Clinical Immunology and Allergy
ISSN 2471-304X
1 5
t h
I n t e r n a t i o n a l C o n f e r e n c e o n
Immunology
T
CR-Tcell therapy is a promising immunotherapy for cancer patients.
A large number of tumour-reactive TCR genes are cloned and need
the preclinical experiments. Therefore, it is very important to establish
an experimental animal model to quickly and effectively evaluate the
function of TCR. The development of stem cell technology provides
a new way to solve these technological bottlenecks. Embryonic stem
cells (ES) / inducible pluripotent stem cells (iPS) can grow infinitely
in
vitro,
are easy to culture, and maintain normal cell karyotype and have
the potential to differentiate into various normal cells, including T cells.
Therefore, we propose to combine TCR and ES technology to produce
single specific T cells using TCR modified ES cells. In order to mimic
human HLA-TCR recognition system in mouse T cells, we use human
and mouse hybrid molecular system of MHC and TCR. The MAGEA1-
specific TCR1367 contained human V (D) J and mouse C gene
fragment was sub cloned into lentiviral vector for the transduction of
mouse ES cells, and then OP9-DL1-HHD cell line was generated with
HHD retroviral vector which express the chimeric MHC molecule HHD
to create human HLA-TCR antigen recognition system in mouse T
cells, TCR1367-ES, OP9 and OP9-DL1-HHD cells were subcutaneously
co-injected into NOD/SCID or NSG mice to generate ES cell-derived
teratoma. 8 weeks later, mature T cells which have single antigen
specificity for anti-tumour antigen could be detected in peripheral
blood and spleen. After isolating these T cells, we found that they could
specifically recognizeMAGEA1 epitopes, and kill MAGEA1+ cells. Using
this simple and low cost TCR-ES cell differentiation technique, NOD/
SCID or NSG mice can be used as a biological generator to produce
antitumor T cells, which can be used to test the functions of various
human TCR genes in preclinical animal experiments.
Antitumour T cells generated from embryonic stem cells
modified by tumour antigen specific TCR
Liangping Li
3
, Weiran Li
1
, Qingyang Li
3
, Chanchan Song
3
and
Yongping Li
1
1
Sun Yan-sen University, Guangzhou, China
3
Jinan University, First Affiliated Hospital, Guangzhou, China
Biography
Liangping Li has completed his PhD from Humboldt-Universität zu Berlin
and Postdoctoral studies from Max-Delbrück-Centrum für Molekulare
Medizin, Berlin, Germany. He is the director of Institute of Clinical Oncology,
Jinan University, First Affiliated Hospital, Guangzhou, China. He has
published several important papers in reputed journals such as Nature
Medicine, Nature Protocol, Blood, Cancer Res. et al. and has been serving
as an Editorial Board Member of several journals.
liangping_li@jnu.edu.cnLiangping Li et al., Insights Allergy Asthma Bronchitis 2018, Volume: 4
DOI: 10.21767/2471-304X-C1-003